Johnson & Johnson has appointed a nationally known bioethicist to create a panel that will make decisions about patients’ requests for potentially lifesaving medicine, responding to an emotional debate over whether companies should allow desperately ill people to have access to the drugs before they are approved. Aaron Kesselheim, associate professor of medicine at Brigham and Women’s Hospital, is quoted.
Trending News
Search for Babesiosis Treatment Gets a New Map
New clues to help fight tick-borne disease
Can an AI ‘Co-Scientist’ Accelerate Cancer Research?
Nearly $7 million funds agentic AI tools to assist investigations into cancer’s most pressing…
First Large-Scale Study Shows How Doctors Use AI in Medicine
Which practitioners use artificial intelligence in the clinic, and what do they ask?